By implementing structured, risk-based, and auditable recordkeeping practices, therapeutic goods manufacturers, testing laboratories, and biotechnology companies can confidently demonstrate that their data management systems are not just “adequate,” but robust, compliant, and ready for inspection and growth.
Data integrity and good documentation practices form the backbone of compliance and scientific rigor in GxP-regulated industries. By adhering to principles such as ALCOA+, ensuring traceable and accurate recordkeeping, validating electronic systems, training personnel, and implementing continuous monitoring, organisations can reliably demonstrate operational maturity.
Transforming laboratory results into defensible evidence requires rigorous adherence to quality systems, data integrity principles, and regulatory compliance standards. By implementing structured processes for data capture, validation, analysis, and documentation, laboratories can ensure results are scientifically robust and legally defensible.
The TGA Compliance Principles 2026 and 2027 provide a structured, risk-based framework for monitoring, enforcing, and supporting compliance with the Therapeutic Goods Act 1989.